ARGX Key Statistics, Chart & Performance
The current stock price of ARGX is 900.76 USD. In the past month the price increased by 5.4%. In the past year, price increased by 48.35%.
ARGX Latest News, Press Relases and Analysis
ARGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.61 | 394.34B | ||
| AMGN | AMGEN INC | 14.69 | 172.98B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.46 | 112.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 73.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 843.18 | 56.81B | ||
| INSM | INSMED INC | N/A | 41.92B | ||
| NTRA | NATERA INC | N/A | 33.00B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.17 | 20.65B | ||
| INCY | INCYTE CORP | 15.06 | 18.98B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.16B |
Related stock screener links
About ARGX
Company Profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Company Info
ARGENX SE - ADR
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND 4811 AH NL
CEO: Tim Van Hauwermeiren
Employees: 1599
Phone: 31763030
ARGENX SE - ADR / ARGX FAQ
What does ARGX do?
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
What is the stock price of ARGENX SE - ADR today?
The current stock price of ARGX is 900.76 USD. The price decreased by -0.05% in the last trading session.
What is the dividend status of ARGENX SE - ADR?
ARGX does not pay a dividend.
How is the ChartMill rating for ARGENX SE - ADR?
ARGX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is ARGENX SE - ADR (ARGX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ARGX.
How many employees does ARGENX SE - ADR have?
ARGENX SE - ADR (ARGX) currently has 1599 employees.
Can you provide the market cap for ARGENX SE - ADR?
ARGENX SE - ADR (ARGX) has a market capitalization of 55.46B USD. This makes ARGX a Large Cap stock.
ARGX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ARGX. When comparing the yearly performance of all stocks, ARGX is one of the better performing stocks in the market, outperforming 89.98% of all stocks.
ARGX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ARGX. ARGX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
ARGX Financial Highlights
Over the last trailing twelve months ARGX reported a non-GAAP Earnings per Share(EPS) of 13.41. The EPS increased by 1512.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.97% | ||
| ROA | 17.84% | ||
| ROE | 21% | ||
| Debt/Equity | 0.01 |
ARGX Forecast & Estimates
25 analysts have analysed ARGX and the average price target is 978.22 USD. This implies a price increase of 8.6% is expected in the next year compared to the current price of 900.76.
For the next year, analysts expect an EPS growth of 939.88% and a revenue growth 94.97% for ARGX